What changed
$ZLAB — BUY 📊 | 6 MONTHS THESIS
🎯 latest | Rev $38M | EPS $-0.46 vs $-0.53 🟢
💡 Consensus models continued large losses and slow margin improvement; the EPS beat and revenue growth (likely 20–25% YoY) indicate earlier operating leverage. The market underappreciates near-term profitability potential and the value of upcoming milestone events.
📉 Reward/risk: 2.4:1
🏢 Business Quality: 7/10 - Diversified commercial products, strong global partnerships, and growing in-house R&D, but still unprofitable and exposed to China biotech volatility.
📊 Valuation: fair — EV/Sales ~6.5x based on estimated $150M TTM revenue and ~$1B enterprise value (market cap $1.8B less ~$800M cash).
🔮 Catalyst: Q1 2025 earnings and potential Phase III data readouts for key assets (e.g., adagrasib, zanubrutinib combos)
💰 Entry: $17.88, stop $14.5, target $26.0
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/ZLAB0617